While the Paris-based OECD has trimmed global growth estimates for 2025 and 2026 to 2.9%, versus 3.1% and 3% previously, the change to its U.S. outlook was more draconian. Growth for 2025 was slashed ...

The updated guidance assumes that Dollar General will be able to mitigate "a significant portion of the potential impact to its cost of goods from tariffs at currently implemented rates," the company ...

The Chinese automaker said Tuesday that its net loss was 6.89 billion yuan, equivalent to $957 million, widening from 5.26 billion yuan a year earlier. Revenue rose 21% to 12.03 billion yuan. Analysts ...

The S&P 500 SPX is only 3.78% off its February highs, after May's record gains, though it remains to be seen if the rally will keep going through the long days of summer. That's as other segments of ...

The nearly century-old Japanese company that founded Toyota Motor in the 1930s plans to go private in a deal that values the now-forklift maker at about $34 billion, with backing from the car giant's ...

Our fair value estimate for Treasury Wine Estates is AUD 12 per share. We assign Treasury a 9% cost of equity, and along with our assumed 6.5% long-term cost of debt, our approximate weighted average ...

Wesfarmers is Australia's best-known conglomerate. Activities span discount department stores, office supplies, home improvement, energy manufacture and distribution, industrial and safety supplies, ...

Although some may hate to admit it, social media influencers focused on financial topics—or “finfluencers”—have become a ...

Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration.

FactSet Research Systems' chief executive, Phil Snow, is retiring after a decade at the helm, and the financial-data provider has hired JPMorgan Chase veteran Sanoke Viswanathan to succeed him.

Agenus struck a $141 million agreement with Zydus Lifesciences that it said will accelerate clinical development, scale global manufacturing and expand patient access to its in-development cancer ...

Rising term premia - the excess return demanded by investors for investing their money over a longer period of time - have been a characteristic of most global bond markets in 2025. And U.S.